Cargando…

COVID‐19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID‐19 pediatric convalescents

BACKGROUND: Studies of anti‐SARS‐CoV‐2 humoral and adaptive response in COVID‐19 non‐vaccinated pediatric convalescents are controversial and further evidence from the pediatric population are needed. OBJECTIVES: To elucidate SARS‐CoV‐2 humoral and memory B‐ and T‐cells responses in pediatric conval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gurevich, Michael, Zilkha‐Falb, Rina, Sonis, Polina, Magalashvili, David, Dolev, Mark, Mandel, Mathilda, Menascu, Shay, Achiron, Anat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827896/ https://www.ncbi.nlm.nih.gov/pubmed/36282137 http://dx.doi.org/10.1111/pai.13863

Ejemplares similares

SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients
por: Gurevich, Michael, et al.
Publicado: (2022)

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
por: Achiron, Anat, et al.
Publicado: (2021)

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod
por: Achiron, Anat, et al.
Publicado: (2022)

In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab
por: Achiron, Anat, et al.
Publicado: (2023)

SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects
por: Achiron, Anat, et al.
Publicado: (2021)

Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients
por: Menascu, Shay, et al.
Publicado: (2020)

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis
por: Gurevich, Michael, et al.
Publicado: (2015)

Faster progression to multiple sclerosis disability is linked to neuronal pathways associated with neurodegeneration: An ethnicity study
por: Harari, Gil, et al.
Publicado: (2023)

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021
por: Achiron, Anat, et al.
Publicado: (2021)

Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: A prospective analysis
por: Menascu, Shay, et al.
Publicado: (2023)

Cytokine prediction of mortality in COVID19 patients
por: Mandel, Mathilda, et al.
Publicado: (2020)

Physical activity behavior in people with multiple sclerosis during the COVID-19 pandemic in Israel: Results of an online survey
por: Kalron, Alon, et al.
Publicado: (2021)

The Design, Development, and Testing of a Virtual Reality Device for Upper Limb Training in People With Multiple Sclerosis: Single-Center Feasibility Study
por: Kalron, Alon, et al.
Publicado: (2022)

RAM-589.555 favors neuroprotective and anti-inflammatory profile of CNS-resident glial cells in acute relapse EAE affected mice
por: Zilkha-Falb, Rina, et al.
Publicado: (2020)

Longitudinal relationships between disability and gait characteristics in people with MS
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?
por: Achiron, Anat, et al.
Publicado: (2021)

Cognitive function in multiple sclerosis: A long-term look on the bright side
por: Harel, Yermi, et al.
Publicado: (2019)

Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2012)

Targeted cognitive game training enhances cognitive performance in multiple sclerosis patients treated with interferon beta 1-a
por: Menascu, Shay, et al.
Publicado: (2021)

Understanding Autoimmune Mechanisms in Multiple Sclerosis Using Gene Expression Microarrays: Treatment Effect and Cytokine-related Pathways
por: Achiron, A., et al.
Publicado: (2004)

Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study
por: Achiron, Anat, et al.
Publicado: (2013)

A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohort
por: Kalron, Alon, et al.
Publicado: (2015)

Motoric cognitive risk syndrome in people with multiple sclerosis: prevalence and correlations with disease-related factors
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Unique Gene Expression Patterns in Human T-cell Lines Generated from Multiple Sclerosis Patients by Stimulation with a Synthetic MOG Peptide
por: Mandel, Mathilda, et al.
Publicado: (2005)

Potential role of indolelactate and butyrate in multiple sclerosis revealed by integrated microbiome-metabolome analysis
por: Levi, Izhak, et al.
Publicado: (2021)

The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis
por: Volfovitch, Yuval, et al.
Publicado: (2022)

The Median Eminence, A New Oligodendrogenic Niche in the Adult Mouse Brain
por: Zilkha-Falb, Rina, et al.
Publicado: (2020)

An Immersive Virtual Kitchen Training System for People with Multiple Sclerosis: A Development and Validation Study
por: Pau, Massimiliano, et al.
Publicado: (2023)

Post-CNS-inflammation expression of CXCL12 promotes the endogenous myelin/neuronal repair capacity following spontaneous recovery from multiple sclerosis-like disease
por: Zilkha-Falb, Rina, et al.
Publicado: (2016)

Humoral and cellular response in convalescent COVID-19 lupus patients
por: Solé, Cristina, et al.
Publicado: (2022)

Alterations in T and B cell function persist in convalescent COVID-19 patients
por: Shuwa, Halima A., et al.
Publicado: (2021)

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
por: Supasa, Piyada, et al.
Publicado: (2021)

Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
por: Hueso, Thomas, et al.
Publicado: (2020)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2009)

Optimizing multiple sclerosis diagnosis: gene expression and genomic association
por: Gurevich, Michael, et al.
Publicado: (2015)

Alterations in B Cell and Follicular T-Helper Cell Subsets in Patients with Acute COVID-19 and COVID-19 Convalescents
por: Kudryavtsev, Igor V., et al.
Publicado: (2021)

COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_na4sd0c4eu9ujll487ehh8rl5q